Article
Investigating the origin of the slow-binding inhibition of HCV NS3 serine protease by a novel substrate based inhibitor.
Antiviral Department, Infectious Disease Research and Advanced Technology, Pharmaceutical Discovery, Abbott Laboratories, Abbott Park, Illinois 60064-6217, USA.
Biochemistry (impact factor:
3.42).
08/2003;
42(29):8862-9.
DOI:10.1021/bi034661v
pp.8862-9
Source: PubMed
-
Citations (0)
-
Cited In (0)
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
active site
apparent indandione inhibition
CH(2)-S compound
CH(2)-S linkage
disulfide exchange
disulfide-linked dimer converts
HCV NS3 protease
HCV protease
hepatitis C virus NS3 serine protease
inhibitory mechanism
mechanisms accounting
modification converts
P1 cysteine
parent compound
S-phenyl disulfide adduct
slow-binding inhibitor
small molecule inhibitors
structural zinc atom
subsequent redox chemistry
sulfhydryl group